Zika virus vaccine: The current state of affairs and challenges posed by antibody-dependent enhancement reaction
Document Type
Article
Publication Date
11-1-2022
Abstract
Infection caused by the Zika virus (ZIKV) can lead to serious neurological complications such as microcephaly in neonates. At present, no approved ZIKV vaccine is available, but few vaccine candidates are undergoing clinical trial. One major challenge faced is antibody-dependent enhancement (ADE) reaction that may provoke severe outcome in subsequent infection by ZIKV or other flaviviruses. Thus, more efforts should be dedicated to understanding ADE in designing a safe and effective vaccine to minimize the consequence of the potentially fatal infection's complications and to tackle potential ZIKV reemergence. This review discusses different types of ZIKV vaccine candidates that are currently underway in various stages of preclinical and clinical evaluations.
Keywords
Antibody-dependent enhancement, Humoral immunity, Pathogenesis, Vaccines, Zika virus
Divisions
fac_med,tidrec
Funders
None
Publication Title
Viral Immunology
Volume
35
Issue
9
Publisher
Mary Ann Liebert, Inc
Publisher Location
140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA